Verification series · the five checks, applied · updated 2026-08-14

Is Hims legit? The verification file

Verdict

Hims is obviously a real company — publicly traded, mass-market — and the legitimacy question in 2026 is really a currency question: after Novo Nordisk's February lawsuit and the March partnership that ended it, Hims stopped advertising compounded GLP-1s and pivoted to brand-forward Wegovy, so most 'Hims tirzepatide' figures circulating (including a ~$299 Hers listing) describe a lane the platform has largely exited.

What checks out

✓ Public company with full regulatory footprint, real clinical operations at scale.

✓ The pivot itself is a legitimacy signal: it resolved its Novo dispute by moving toward brand product.

✓ Its brand-Wegovy lane is a genuine offer worth cross-shopping against NovoCare direct.

What we flag

⚠ Aggregator tables still carry pre-pivot compounded prices (~$329 historical; Hers ~$299 in the April comparison) — treat these as museum pieces pending current-checkout confirmation.

⚠ Tirzepatide specifically was never the pivot's subject (the deal was semaglutide), so the platform's tirzepatide story is thinner than its brand suggests.

⚠ Legacy compounded subscribers should get transition terms in writing.

What the review ecosystem says

Hims' review corpus is enormous — public-company scale — and for the GLP-1 lane specifically it's a time-series more than a snapshot: pre-February reviews describe the compounded program (price praise, standard telehealth gripes), the spring's reviews chronicle the lawsuit-to-partnership whiplash, and the current era's describe the brand-Wegovy pivot, with legacy compounded subscribers reporting transition experiences that range from seamless to confused. That arc is the finding: nothing in the record impeaches Hims' legitimacy — a publicly traded company that resolved a manufacturer dispute by moving toward brand product made the legitimacy-enhancing choice — but it does mean most circulating 'Hims GLP-1' information describes a program that no longer exists in that form, and reviews of a discontinued lane are history, not guidance.

The checkout walk: what to verify before paying

The Hims walk is unusually simple because the question is existential rather than fine-print: open the current flow and record what is actually offered — brand Wegovy through the Novo partnership, any remaining compounded option, and at what prices — because our dataset's figures (~$329 historical; Hers ~$299 in the April comparison) predate the pivot and are flagged as museum pieces. If brand Wegovy is the offer, cross-shop it directly against NovoCare's own $149 oral / brand-injectable pricing, since a partnership markup is a real possibility worth ten minutes. Legacy compounded subscribers: get transition terms in writing — what you'll receive, at what price, from when. Who it fits: existing Hims users who value one-platform convenience and confirm the current offer beats direct channels. Who should pass: anyone shopping the compounded floor — that lane's era at Hims has largely ended, and the ledger lists where it lives now.

What would close the file

A current-checkout capture of what the platform actually offers, brand and compounded, post-pivot. Send documentation through corrections — reader receipts have already changed this dataset, the 48-hour clock applies, and operators are welcome to submit on the record.

Run the checks yourself

Every verdict on this page reduces to the five checks from the fraud field guide: a real prescription gate, a named pharmacy you can run through your state's license lookup, normal payment rails, a price that clears the market's real floor, and — for any oral format — human absorption data on request. They take five minutes, they're free, and they don't require trusting us: we built them so you wouldn't have to.

Fact sheets: Hims and Hers. The full pivot story: Ro vs Hims.

FAQ

Is Hims legit for weight loss?

Yes — a publicly traded telehealth company whose GLP-1 lane pivoted to brand-forward Wegovy after its February 2026 dispute with Novo Nordisk resolved into a March partnership. The legitimacy is solid; the circulating compounded prices are outdated.

Does Hims still sell compounded semaglutide or tirzepatide?

Largely no — post-partnership, Hims stopped advertising compounded GLP-1s and emphasizes brand Wegovy. Tirzepatide was never the partnership's subject, making its tirzepatide story thinner than the brand suggests. Verify the live checkout.

Is Wegovy through Hims cheaper than NovoCare?

Cross-shop before assuming — NovoCare's direct pricing (oral Wegovy ~$149) is the benchmark any partnership offer must beat, and platform convenience sometimes carries a markup.